Member Info for miavoce

Hi ElderlyBird,

the time to approach the MHRA will be when we have a validated test that can be shown to deliver patient benefit. The first one of these is likely to be the Ovarian Triage test which should be validated by the end of this year. I'm not sure how the process works but I guess in principle a case would then be presented to the MHRA to make the test available as standard prior to surgery for women with a pelvic mass.

Thanks all - makes sense now :-)

In my dream last night Lindy was in my house (don't know why). She was diabetic and needed to eat - she wanted a custard tart so we headed out to the local co-op. Try as I might I could not find the co-op (despite it being round the corner from me) and Lindy ended up buying a very large piece of meat and potato pie from a street vendor (which she said she preferred to a custard tart anyway).

I'm struggling to put a sensible interpretation on this but you are welcome to have a go if you can divine the meaning.

Coincidence that jakeyork turns up with his 'negative holder' patter shortly followed by ElderlyBird with her 'holder who thinks FDA wont grant approval' patter....maybe, maybe not.

Ha ha Phantom25 - no, all you need to do is click on the poster's name and you can quickly see all their previous posts :-)

Hi ElderlyBird

Buzz_Lightyear has explained why this device will be good for pharma but irrespective of that could you share some examples to support your assertion that:-

'the FDA and MHRA do not have a good record at making decisions on new systems that will cut down on drugs'

You have basically said the same thing in each of your 4 posts over the last 2 years but haven't provided any supporting evidence for FDA or MHRA - I'd be interested to see the examples.

Thanks

Hi jakeyork

as you might know the Parsortix system enables the capture and harvesting of live cancer cells from blood whereas Grail (and other ctDNA based systems) simply detect DNA from dead cancer cells. The live cells enable clinicians to understand much more about the cancer (RNA, protein expression)which informs decisions about treatment in a way that DNA alone simply cannot.

The future for Parsortix is very bright indeed and isn't threatened by Grail or its peers - as has been stated before they are complementary.

Once Parsortix has FDA approval the brakes will be off on much wider pharma use of the system, partnerships with the like of Abbott, further lab contracts, and (IMO) a takeover in the not too distant future.

I see from your earlier posts that you have bought, sold, increased, reduced etc etc over the last few months. If you understand the investment case for Angle them surely you should just buy and hold rather than being influenced by the daily gyrations of the share price. If you don't understand the investment case then probably better to invest elsewhere for the sake of your nerves ;-)

He did a pretty rubbish job of describing the needle free delivery method - made it sound barbaric instead of virtually painless.

Thanks labrow - great to have eyes on the ground !!

To clarify, Andrew N has made the point that the same blood sample can be used for both CTC capture and ctDNA capture. Parsortix is used to capture the CTC's and then the residual blood can be used to do ctDNA analysis using a system such as Grail.

Thanks all for replies.

The 'Duration' section says:-

'After a screening period of up to 15 days, participants will receive SCOV1 injections on Day 1 and Day 29. The first SCOV2 injection will be given at the earliest available opportunity from Day 113 (expected availability is between Day 113 and Day 169), with the second SCOV2 injection occurring 4 weeks later (between Day 141 and D197). Final assessments for safety and immunogenicity will occur 6 weeks after the second SCOV2 injection. Total participation is therefore expected to be between 28 and 36 weeks.'

Does this mean that the first SCOV2 injection won't be given until at least 16 weeks from now ?

Hi C7 - Zakari is 100% owned by Scancell and therefore whatever fraction of Scancell LD's shares and options cover includes the same fraction of Zakari. If Zakari were to be listed separately the there would be the opportunity to grant options over Zakari shares.

I wonder if they wanted to get these 9m options awarded before any news which triggers a price hike (and this would mean awarding the options at a higher exercise price). If this is indeed the case then this may mean that news isn't too far away.

I went for a walk just now and saw a van on the side of which it said:-

De NOVO Kitchens

Was there ever a surer sign that the FDA response is imminent. Based on this omen I'm thinking we'll get it this week.

Ruck

would be worth an sp of £50 on a PE of 15.

There was an agreement 4th Sept 2019 (1st Avidimab collaboration) - maybe you saw this LL ?

Rats,

my sincere condolences.

Davetherave1 - if IG buys or sells and shares at all it has to be disclosed via RNS.

One of the purposes of the placing in June 2019 (which raised 18m) was stated as:-

- GBP2 million to enable key product development including enhancements to the Parsortix system, development of a proprietary Parsortix harvest chip and a sample-to-answer imaging solution inter alia to progress the Abbott partnership;

Perhaps this is coming to fruition ?